LLP Abingworth
CIK 1397144 · last filed 2024-02-12
LLP Abingworth is a corporate insider who has filed 37 SEC Form 4 insider transactions across 12 companies since 2011. The most recent filing shows the insider bought $2.5M of JSPRW on Feb 12, 2024. Across all open-market trades the lifetime net is −$206.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $153.9M across reported positions. 5 SEC filings were submitted jointly with CG Subsidiary Holdings L.L.C.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMRN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LONDON SW1Y 4AH
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPRW) Delisted | 10%+ Owner | 1,066,189 | $0.00 | $213 | $2.46M | 2 | 2024-02-12 |
| VERA | 10%+ Owner | 2,966,875 | $30.78 | $91.32M | $8.30M | 2 | 2022-08-19 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | 10%+ Owner | 1,201,507 | $53.01 | $63.69M | $5.50M | 2 | 2022-03-31 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 1,164,127 | $54.99 | $64.02M | $4.05M | 1 | 2022-02-01 |
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | 10%+ Owner | — | $0.00 | — | $0 | 1 | 2021-12-17 |
| PSNL | 10%+ Owner | 3,753,340 | $15.93 | $59.79M | -$38.49M | 6 | 2020-10-21 |
| PCVX | 10%+ Owner | — | $67.31 | — | $0 | 2 | 2020-06-16 |
| PRTO | 10%+ Owner | 53,613 | $26.47 | $1.42M | $0 | 6 | 2019-11-14 |
| SOLENO THERAPEUTICS INC (SLNOW) Delisted | 10%+ Owner | 6,969,272 | — | — | $2.76M | 1 | 2019-10-29 |
| Sientra, Inc. (SIEN) Delisted | 10%+ Owner | 248,049 | $0.17 | $43.2K | $11.23M | 2 | 2018-05-09 |
| CHIASMA, INC (CHMA) Delisted | 10%+ Owner | 2,080,595 | $3.76 | $7.82M | $0 | 2 | 2016-03-09 |
| AMRN | 10%+ Owner | 114,058 | $11.67 | $1.33M | -$201.86M | 10 | 2012-04-26 |
Recent Filings
37 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-12 | Jasper Therapeutics, Inc. (JSPRW) Delisted | Buy (P) | +190,000 | $2.46M | EDGAR |
| 2022-08-19 | VERA | Mixed | — | -$91.9K | EDGAR |
| 2022-03-31 | SOLENO THERAPEUTICS INC (SLNO) Delisted | Mixed | +7,720,000 | $0 | EDGAR |
| 2022-03-23 | Jasper Therapeutics, Inc. (JSPRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-01 | Sierra Oncology, Inc. (SRRA) Delisted | Mixed | +437,471 | $7.84M | EDGAR |
| 2021-12-17 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-18 | VERA | Mixed | +2,960,231 | $8.50M | EDGAR |
| 2020-10-21 | PSNL | Sell (S) | −130,486 | -$3.61M | EDGAR |
| 2020-10-20 | PSNL | Sell (S) | −290,641 | -$7.99M | EDGAR |
| 2020-10-16 | PSNL | Sell (S) | −85,625 | -$2.32M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.